David Christopher Lung
-
Research
![Photo of [The Lancet] Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial](https://fightcovid19.hku.hk/content/uploads/2020/02/cover-yuen-kwok-yung-1024x538-1-390x220.png)
[The Lancet] Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
The Lancet, May 8 2020 Ivan Fan-Ngai Hung,Kwok-Cheung Lung,Eugene Yuk-Keung Tso,Raymond Liu,Tom Wai-Hin Chung,Man-Yee Chu,Yuk-Yung Ng,Jenny Lo,Jacky Chan,Anthony Raymond Tam,Hoi-Ping…
Read More » -
Research
![Photo of [The Lancet Microbe] Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study](https://fightcovid19.hku.hk/content/uploads/2020/05/fusion-medical-animation-EAgGqOiDDMg-unsplash-390x220.jpg)
[The Lancet Microbe] Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study
The Lancet Microbe, 21 April 2020 Hin Chu, Jasper Fuk-Woo Chan, Terrence Tsz-Tai Yuen, Huiping Shuai, Shuofeng Yuan, Yixin Wang,…
Read More »